Results 161 to 170 of about 88,903 (261)

Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and Rehabilitation [PDF]

Occupational Medicine, 2017
openaire   +2 more sources

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Increased Plasma Microbial tDR‐1 in At‐Risk Individuals Is Associated With Decreased Conversion to Clinical Rheumatoid Arthritis and Reduces an In Vitro Macrophage Type 1 Interferon Response

Arthritis &Rheumatology, EarlyView.
Objective Microbial small RNAs can regulate human genes. Higher plasma concentrations of microbial transfer RNA (tRNA)‐derived RNA‐1 (tDR‐1) were previously associated with lower rheumatoid arthritis (RA) disease activity. This study examined whether tDR‐1 concentrations differ in anticyclic citrullinated peptide‐3 positive (CCP3+) at‐risk individuals (
Anastasiia Phothisane, Tulsi K. Joishy, Carolina Ramirez‐Becerra, Qiong Wu, Jennifer Seifert, Marie L. Feser, Jill M. Norris, M. Kristen Demoruelle, LauraKay Moss, Kevin D. Deane, V. Michael Holers, Michelle J. Ormseth   +11 more
wiley   +1 more source

FLYWHEEL TRAINING IN MUSCULOSKELETAL REHABILITATION: A CLINICAL COMMENTARY. [PDF]

Int J Sports Phys Ther, 2019
Wonders J.
europepmc   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

Arthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, BSRBR‐RA Contributors Group, Kimme L Hyrich   +8 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Response to In-Home Virtual Reality Program for Chronic Lower Back Pain: A Randomized Sham-Controlled Effectiveness Trial in a Clinically Severe and Diverse Sample

Mayo Clinic Proceedings: Digital Health
Jesper Knoop, PhD, Syl Slatman, MSc, Bart Staal, PhD   +2 more
doaj   +1 more source

Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database

Arthritis &Rheumatology, Accepted Article.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic, Pascal Claudepierre, Tat Thang Vo, Tran Trong Khoi Le, Siham Iggui, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas   +7 more
wiley   +1 more source